Paper Details

  1. Home
  2. Paper Details

[Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].

Author: AlifirovaV M, BoykoA N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This international study evaluated the efficacy and safety of glatiramer acetate (GA) in patients with relapsing-remitting multiple sclerosis (RRMS). The study, including 166 patients from Russia, demonstrated the high efficacy, safety, and tolerability of GA (40 mg/ml administered 3 times a week) compared with placebo. The findings suggest that this regimen is a convenient option for RRMS patients, potentially improving treatment adherence.
Paper Details　
Original Abstract of the Article :
The article presents the results of an international study on the efficacy and safety of glatiramer acetate (GA) (40 mg/ml administered 3 times a week) compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS). This study was conducted in 142 sites in 17 countries includin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.17116/jnevro2017117111135-139

データ提供：米国国立医学図書館（NLM）

Glatiramer Acetate: A Beacon of Hope for Multiple Sclerosis

Multiple sclerosis (MS), a complex autoimmune disease, can be as unpredictable as a desert sandstorm, affecting different individuals in various ways. This study investigates the efficacy and safety of glatiramer acetate (GA) in treating relapsing-remitting MS (RRMS).

A Promising Path: GA's Effectiveness in RRMS

The study found that GA, administered three times a week, demonstrated significant efficacy and a favorable safety profile in patients with RRMS. This is like finding a reliable camel with a steady pace, offering a path towards managing the challenges of MS.

A Journey Towards Stability: GA's Potential for RRMS Treatment

This research suggests that GA might be a valuable treatment option for RRMS, offering potential benefits in terms of managing disease progression and improving quality of life for patients. It's like finding a stable oasis in the desert of MS, providing a sense of security and hope for the future.

Dr. Camel's Conclusion

This research offers a glimpse of hope in the desert of MS, highlighting the potential benefits of GA for RRMS patients. It's a reminder that even in the face of complex and unpredictable diseases, there are ongoing efforts to develop effective treatment strategies, offering a path towards a brighter future.
Date :
  1. Date Completed 2018-11-01
  2. Date Revised 2018-11-01
Further Info :

Pubmed ID

29265099

DOI: Digital Object Identifier

10.17116/jnevro2017117111135-139

Related Literature

Article Analysis
・Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.